UNSPSC 51331601: Oxyfenamate or hydroxyphenamate

This classification denotes an antipsychotic agent with the molecular formula C11H15NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MD0414799X, chemically known as 1,2-butanediol, 2-phenyl-, 1-carbamate but generally known as hydroxyphenamate, which bears US NIH Compound Identifier 5752. European Medicines Agency schedules Oxyfenamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09565MIG.

The term OXYFENAMATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). Oxyfenamate or hydroxyphenamate bears US NLM identifiers UMLS ID C0301410 and NCI Concept Code C76011. SMILES: CCC(COC(=O)N)(C1=CC=CC=C1)O.

UNSPSC 51331601 Oxyfenamate or hydroxyphenamate, a Commodity code, shows limited recent alignment with its nominal scope in state and local procurement activity. The three most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are oxyfenamate or hydroxyphenamate formulations. The mismatch suggests either tagging inconsistency in the source data or that this Commodity code does not reflect active state and local purchasing patterns for its designated product class. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). The work being solicited centers on supply chain procurement for pharmacological products delivered through wholesaler networks or direct manufacturer relationships, with compliance requirements including cGMP certification, Drug Supply Chain Security Act adherence, and FDA compliance.

Recent activity clusters in Florida and Minnesota through MMCAP's multistate cooperative vehicle, with Texas participating through a preliminary RFI phase. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: deadline date appears inconsistent with posting date). The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, exploring vendor capabilities for direct-to-manufacturer prescription programs without a formal competitive timeline. MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across participating states and Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The code itself shows no current state and local activity specifically targeting oxyfenamate or hydroxyphenamate procurement.